Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy

Gwo Yaw Ho^{1,2,3,4^}, Elizabeth L. Kyran^{1,2,5^}, Justin Bedo^{1,6^}, Matthew J. Wakefield^{1,7^}, Darren P. Ennis^{8,9}, Hasan B. Mirza⁸, Elizabeth Lieschke^{1,2}, Cassandra J. Vandenberg^{1,2}, Olga Kondrashova¹, Rosie Upstill-Goddard⁹, Ulla-Maja Bailey⁹, Suzanne. Dowson⁹, Patricia Roxburgh^{9,10}, Rosalind M. Glasspool^{9,10}, Gareth Bryson¹¹, Andrew V. Biankin⁹, Susanna L. Cooke⁹, on behalf of the Scottish Genomes Partnership, Gayanie Ratnayake³, Orla McNally^{3,7}, Nadia Traficante^{12,13}, Australian Ovarian Cancer Study^{12,14}, Anna DeFazio^{14,15,16}, John Weroha¹⁷, David D. Bowtell^{12,13}, Iain A. McNeish^{8,9,10#}, Anthony T. Papenfuss^{1,2,12,18#}, Clare L. Scott^{1,2,3,7,13#}, Holly E. Barker^{1,2#*}

¹The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3052, Australia.

²Department of Medical Biology, University of Melbourne, Parkville, Victoria, 3010, Australia.

³The Royal Women's Hospital, Parkville, Victoria, 3052, Australia.

⁴School of Clinical Sciences, Monash Health, Monash University, Clayton, Victoria, 3800, Australia.

⁵Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK.

⁶Department of Computing and Information Systems, the University of Melbourne, Parkville, Victoria, 3010, Australia.

⁷Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria 3010, Australia.

⁸Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0NN, UK.

⁹Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow G61 1QH, UK.

¹⁰Beatson West of Scotland Cancer Centre, Glasgow G12 0NN, UK.

¹¹Department of Pathology, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.

¹²Research Division, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria, 3000, Australia.

¹³Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria, 3010, Australia.

¹⁴Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.

¹⁵The University of Sydney, Sydney, NSW 2145, Australia.

¹⁶Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, 2145, Australia.

¹⁷Department of Oncology, Mayo Clinic, Rochester, Minnesota, US.

¹⁸Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, 3010, Australia.

[^] # authors contributed equally to work

* Corresponding author Dr Holly Barker

Contact details barker.h@wehi.edu.au

Abstract

Ovarian carcinosarcoma (OCS) is an aggressive and rare tumour type with limited treatment options. OCS is hypothesised to develop via the combination theory from a single progenitor, resulting in carcinomatous and sarcomatous components, or alternatively via the conversion theory, with the sarcomatous component developing from the carcinomatous component through epithelial-to-mesenchymal transition (EMT). We show OCS from 18 women to be monoclonal through analysis of DNA variants from isolated carcinoma and sarcoma components. RNA sequencing indicated the carcinoma components were more mesenchymal when compared with pure ovarian carcinomas, supporting the conversion theory. We used pre-clinical OCS models to test the efficacy of microtubule-targeting drugs, including eribulin, which has been shown to reverse EMT characteristics. We demonstrated that microtubule inhibitors, vinorelbine and eribulin, were more effective than standard-of-care platinum-based chemotherapy. Eribulin reduced mesenchymal characteristics, N-MYC expression and cholesterol biosynthesis. Finally, eribulin induced a strong immune response, supporting immunotherapy combinations in the clinic.

Introduction

Ovarian carcinosarcoma (OCS), also known as malignant mixed Müllerian tumour, is a heterogeneous cancer with poor prognosis¹, accounting for 1-4% of ovarian malignancies^{2,3}. These tumours contain both epithelial (carcinoma) and mesenchymal (sarcoma) components³.

Molecular analysis suggests that most OCS are monoclonal⁴⁻⁹, with two theories for OCS histogenesis: the combination theory, where a single stem cell differentiates early to form the two components; and the conversion theory, where the carcinoma undergoes epithelial-to-mesenchymal transition (EMT) to form the sarcomatous component¹⁰.

TP53 mutations and loss of heterozygosity (LOH) of 17p, and consequent chromosomal instability, are common in OCS^{7,8,11-14}. Mutations in *PIK3CA*, *PTEN*, *KRAS*, *FBXW7*, *CTNNB1*, and *RBI* are observed frequently^{5,8,9,13,15-17}, whilst mutations in *ARID1A*, *ARID1B*, *KMT2D*, *BAZ1A*, *BRCA1*, *BRCA2*, and *RAD51C* have also been reported^{8,15-19}. One study also identified recurrent mutations in the genes encoding histones H2A and H2B (*HIST1H2AB/C*, *HIST1H2BB/G/J*) that play a role in EMT⁹. Only one study has analysed gene expression in the separate components, finding a strong positive correlation of EMT score with sarcoma content as well as methylation of the EMT-suppressing miRNAs miR-141/200a/200b/200c/429⁸.

EMT can be induced through aberrant expression of the high-mobility-group AT-hook protein 2 (HMGA2) and subsequent activation of the TGF β signalling pathway²⁰. HMGA2 binds preferentially to AT-rich DNA sequences in a histone-independent manner²¹⁻²⁴. HMGA2 is not expressed in most adult tissues^{25,26}, but high expression has been observed in many cancers and is correlated with metastasis and chemotherapy resistance²⁷⁻³¹. HMGA2 expression is thought to be largely controlled by the microRNA *let-7*³²⁻³⁵. Other downstream target genes of *let-7* include *MYCN* and *LIN28B*, whilst *LIN28B* inhibits maturation of *let-7*³⁶, reinforcing both low and high expression states and acting as a bistable switch. Up-regulation of the N-MYC/*LIN28B* pathway has been observed in the aggressive C5 subset of ovarian or fallopian tube high-grade serous carcinoma (HGSC) and in other aggressive cancer subtypes, and is indicative of poor prognosis³⁶⁻³⁸. Furthermore, high HMGA2 expression has been observed in 60% of OCS cases³⁹. We hypothesised that up-regulation of the N-MYC/*LIN28B* pathway and subsequent expression of HMGA2 may be a key driver of OCS, and drugs that target EMT may be effective.

Eribulin is a microtubule-targeting drug that binds to the plus (β tubulin exposed) end of microtubules resulting in mitotic blockade^{40,41}. *In vitro*, *in vivo* and human studies show that eribulin can reverse EMT, leading to favourable intra-tumoral vascular remodelling, reduced cell invasion, increased cell differentiation⁴²⁻⁴⁶ and modulation of the tumour-immune

microenvironment⁴⁷. Eribulin has completed Phase III trials for metastatic breast cancer, soft-tissue sarcoma and non-small cell lung cancer (NSCLC). It has Therapeutic Goods Administration (TGA) approval for treatment of advanced breast cancer and liposarcoma^{47,48}. We hypothesised that eribulin may be effective against OCS tumours due to its role in reversal of EMT characteristics.

Here we present mutation, copy number and gene expression analyses of separate components from an OCS cohort. We have used a unique genetically engineered mouse model (GEMM) and patient-derived xenograft (PDX) models of OCS to assess the efficacy of a range of microtubule-targeting drugs and to determine the mechanism of action of eribulin, a drug with significant activity in these models.

Results

Mutation and copy number profile of OCS was similar to HGSC

We identified eighteen women diagnosed with OCS, seventeen with high-grade serous carcinoma (HGSC) and one with grade 2 endometrioid histology in the carcinoma component. Twelve associated metastatic samples were also available. Full clinical details are shown in Supplementary Table S1 and Supplementary Figure S1. Targeted sequencing of 377 genes in macro-dissected carcinoma and sarcoma components as well as metastases was performed (Supplementary Tables S2-S7; Supplementary Figure S2).

Overall, OCS samples had genomic profiles similar to HGSC, with near-ubiquitous *TP53* mutation (17/18 cases, including 17/17 with HGSC pathology), *CCNE1* amplification (4/18 cases), *BRCA2* loss or mutation (4/18 cases), *KRAS* mutation and amplification (4/18 cases), *PIK3CA* mutation and amplification (4/18 cases), *NF1* or *CDKN2A* mutation or disruption by rearrangement (2/18 cases each), *RBI* deletion (2/18 cases), *PTEN* mutation (2/18 cases) and *MYC* or *MYCN* amplification (1/18 and 2/18 cases, respectively) (Figure 1a). Overall mutational burden was low (mean 1.2, median 0.87 mutations/MB sequenced), which did not differ between carcinoma and sarcoma (Figure 1b, Supplementary Table S8). However, as with HGSC, the genomes were structurally unstable with an average of 3.3 high-level gains and 1.4 likely homozygous deletions called per sample (Supplementary Figure S3).

Only WW00163 lacked a *TP53* mutation. It had mutations in *KRAS* and *ERBB2* (Figure 1a) together with a subclonal mutation of *KMT2C* and lacked the genomic chaos typical of HGSC (Supplementary Figure S4), in keeping with an origin of endometrioid carcinoma.

Based on point mutation profiles, there were no consistent differences between the sarcoma and carcinoma components. In all cases, the two components shared at least one point mutation, demonstrating a shared clonal origin. Half of carcinoma-sarcoma pairs (8/16) shared all point mutations while the others gained additional mutation(s) in one or both components. On average, carcinoma-sarcoma pairs differed by only a single mutation (range 0-7). These data indicate that these tumours are monoclonal, which supports both the conversion and combination theories of carcinogenesis.

By contrast, there were more copy number changes between the carcinoma and sarcoma components, with an average of 10.6 genes having a different copy number state between the two (range 0-36) (Supplementary Figures S3 and S4; Supplementary Table S6). The most commonly different genes were *FGF3* and *MDM2* (Supplementary Table S7). However, these differences did not appear to be focal or high level, perhaps suggesting that these genes are not specific targets of alteration between carcinomas and sarcomas. Instead these chromosomal differences may arise due to ongoing chromosomal instability. Case WW00169 had neither mutation nor copy number differences between the carcinoma and sarcoma components.

Interestingly, in some cases metastases showed substantial genomic divergence from their corresponding primary, indicative of an early seeding to the metastatic sites (Figure 1a). In addition to two cases (WW00154, WW00158) where the metastasis either gained three mutations or lost four, a third case (WW00157) diverged in several likely driver copy number events including loss of *BRCA2* between the carcinoma and its corresponding metastasis (Supplementary Tables S4, S6 and S7).

OCS had EMT-like and N-MYC pathway gene expression patterns

We next undertook RNA sequencing (RNAseq) on isolated carcinoma (n=13) and sarcoma (n=9, 7 paired with carcinoma) components (Supplementary Figure S5; Supplementary Tables S9-S12).

Using an EMT expression signature derived from uterine carcinosarcoma⁴⁹, we found a highly significant enrichment of EMT in carcinosarcomas, compared with the TCGA cohort of ovarian HGSC (TCGA-OV; n=379)⁵⁰. This enrichment was predominantly driven by the sarcoma component ($p<0.0001$; Figure 1c) and was confirmed using other reported EMT signatures⁵¹⁻⁵³ (Supplementary Figure S6). Interestingly, the carcinoma components also had significantly higher EMT scores than the TCGA-OV cohort, suggesting that the OCS carcinoma component was either predisposed to undergo sarcomatous transformation or already transitioning to sarcoma ($p<0.0001$; Figure 1c). Together, these data support the conversion theory of OCS development.

To study the N-MYC/LIN28B pathway specifically, we analysed *MYCN*, *LIN28B* and *HMGA2* expression in the same dataset. *LIN28B* and *HMGA2* were significantly up-regulated compared to the TCGA-OV cohort ($p<0.0001$ for both; Figure 1d).

p53 inhibition and up-regulation of the N-MYC/LIN28B pathway in fallopian tube secretory epithelial cells gave rise to OCS

We established an OCS GEMM by directing both p53 inhibition and N-MYC/LIN28B pathway up-regulation to the fallopian tube secretory epithelial cell (FTSEC) via the PAX8 promoter⁵⁴⁻⁵⁷. The resulting founder tumour (T0) and stable cell line derived from a first passage tumour (T1) (OCS GEMM cells) were used for subsequent experiments (Figure 2a; Supplementary Tables S13 and S14).

IHC analysis revealed high p53 expression, in keeping with SV40 TAg-mediated accumulation⁵⁸ (Figure 2b). Tumours expressed cytokeratin (pan-CK) in approximately 5% and vimentin in approximately 95% of the regions analysed, indicating a predominantly sarcomatous phenotype (Figure 2b). RNA sequencing confirmed up-regulation of *Lin28b* and *Mycn* in the tumours and up-regulation of *Lin28b* and *Hmga2* in the cell line, relative to control fallopian tubes (Figure 2c; Supplementary Table S15), whilst quantitative RT-PCR confirmed elevated expression of *Lin28b* in both the tumour and cell line (Supplementary Figure S7).

GEMM tumours were resistant to current standard-of-care treatments but responded to the microtubule inhibitors vinorelbine and eribulin

We assessed the *in vivo* response of GEMM tumours to standard-of-care HGSC therapies; cisplatin, pegylated liposomal doxorubicin (PLD) and paclitaxel. Overall, the tumours were

refractory to all three treatments, as the time to progressive disease (PD) was the same as for vehicle treatment. PLD and cisplatin failed to demonstrate any meaningful response in the GEMM tumours (Figure 3a), although paclitaxel demonstrated modest responses with an increase in median time-to-harvest (TTH) from 15 to 36 days compared to vehicle treatment (Table 1, $p=0.0101$, respectively). By contrast, significant tumour regression was observed in all tumours treated with the microtubule inhibitor vinorelbine leading to improvement of median TTH (15 days (vehicle) vs 81 days (vinorelbine); Figure 3a, Table 1; $p<0.0001$). Eribulin also resulted in significant tumour regression in all tumours leading to improvement of median TTH (15 days (vehicle) vs 46 days (eribulin); Figure 3a, Table 1; $p<0.0001$). Expression of Ki67 in the tumours was reduced one week after mice received a single dose of eribulin (Figure 3b).

Eribulin treatment reduced adhesion, invasion and branching of the OCS GEMM cell line

In vitro functional assays showed eribulin reduced both adhesion to collagen matrices (Figure 3c; $p=0.024$) and invasion through extracellular matrices of OCS GEMM cells (Figure 3c; $p=0.0042$), compared to DMSO, and reduced branch formation in 3D collagen growth assays (Figure 3d). Western Blot analysis determined a reduction in expression of the mesenchymal markers ZEB1, N-cadherin, vimentin and HMGA2 in OCS GEMM cells exposed to eribulin (Figure 3e).

A cohort of OCS PDX models with N-MYC/LIN28B pathway up-regulation recapitulated the biphasic and heterogeneous nature of OCS

We next expanded and characterised six PDX models of OCS with varying degrees of carcinoma and sarcoma, all harbouring loss or mutation of TP53 (Figure 4a; Supplementary Table S16). The heterogeneous characteristics of the PDX cohort resembled the human OCS tumour landscape. Furthermore, all PDX models expressed HMGA2, suggesting the N-MYC/LIN28B pathway was up-regulated. Over time, a purely sarcomatous lineage (PH003sarc) arose from the original mixed PH003 model (called PH003mixed). RNAseq data revealed that all PDX had higher HMGA2 expression and EMT scores than the TCGA-OV cohort (Figures 4b and 4c). The most sarcomatous PDX models (PH003sarc and PH592) had higher EMT scores than models containing regions of pure carcinoma (PH419 and PH003mixed). By Western Blot, expression of vimentin was highest in PH142, PH003mixed

and PH003sarcoma. PH419 exhibited the lowest expression of vimentin and PH006 and PH592 had intermediate expression (Figure 4d).

Platinum based chemotherapy was ineffective in OCS PDX

In vivo, four of six PDX were refractory to cisplatin as based on our previously published criteria⁵⁹, failing to achieve any meaningful tumour response and developing progressive disease (PD) whilst on cisplatin therapy (D1-18) (Figure 5a and Supplementary Figure S8). Initial tumour regression was observed in PH142 and SFRC01040 but PD occurred by day 42 and day 60 respectively, defining both as cisplatin resistant PDX⁵⁹ (Table 2).

Microtubule-targeting agents, such as paclitaxel, vinorelbine and eribulin, were effective in OCS

Microtubule-targeting agents induced tumour regression and showed an improvement of median TTH in most OCS PDX models. Three PDX (SFRC01040, PH419 and PH006) were classified as sensitive to paclitaxel according to the same criteria used for cisplatin⁵⁹, two were resistant (PH142 and PH592) and one was refractory (PH003) (Figure 5a and Supplementary Figure S8). Indeed, all models displayed an improvement in median TTH compared with vehicle, except for PH003, with four models also displaying an improvement in median TTH compared with cisplatin (Table 2).

Three of six OCS PDX (SFRC01040, PH142 and PH006) were sensitive to vinorelbine, two resistant (PH419 and PH592) and one refractory (PH003) (Figure 5a and Supplementary Figure S8). Interestingly, the more sarcomatous PDX models, PH003 and PH592, were less sensitive to vinorelbine than were the more carcinomatous models. Significant improvements in median TTH compared with vehicle were observed for all models except PH003, and in four models compared with cisplatin (Table 2).

Lastly, three of six PDX models (SFRC01040, PH419 and PH006) were sensitive to eribulin treatment, two were resistant (PH142 and PH592) and one was refractory (PH003) (Figure 5a and Supplementary Figure S8). Interestingly, near complete responses to eribulin were observed in three PDX (SFRC01040, PH419 and PH006). Significant improvements in median TTH compared to vehicle and cisplatin were observed for five models and four models, respectively (Table 2). Eribulin treatment of PH592, which was predominantly sarcomatous, resulted in significant tumour stabilisation to 40 days followed by marked tumour regression

between days 60 to 80 before rapid disease progression. Even for the most aggressive model, PH003, eribulin treatment resulted in a statistically significant improvement in median TTH, albeit of short duration (8 days (vehicle) vs 25 days (eribulin) ($p=0.0003$) and 15 days (cisplatin) vs 25 days (eribulin) ($p=0.0044$)) (Table 2).

It was noted that one lineage of the sarcomatous PDX PH592 was markedly more sensitive to cisplatin treatment, denoted PH592-B, compared with the more cisplatin resistant, PH592-A lineage (median TTH of 15 days (PH592-A) vs 71 days (PH592-B); $p<0.0001$) and similarly, was more sensitive to eribulin (92 days (PH592-A) vs 102 days (PH592-B); $p=0.0240$) (Supplementary Figure S9 and Supplementary Table S17).

***In vivo* eribulin treatment reduced the expression of mesenchymal markers, including HMGA2, in OCS PDX tumours**

PDX tumours were harvested one week after mice received a single dose of eribulin (or DPBS vehicle control) and expression of EMT markers was assessed by western blotting and IHC. Eribulin reduced expression of the mesenchymal marker HMGA2 as well as ZEB1 and N-cadherin in most models (Figures 5b-d; Supplementary Figure S10).

Reduced cholesterol biosynthesis and increased immune activation was implicated in the response of a subset of OCS to eribulin

RNAseq analysis of PDX tumours harvested one week after a single dose of eribulin (Supplementary Table S15) indicated significant down-regulation of genes related to the GO terms protein targeting to membrane, translational initiation, and regulation of cholesterol biosynthesis, and up-regulation of genes related to the GO term immune activation (Figure 5e; Supplementary Tables S18-S21). Interestingly, significantly down-regulated genes included eight genes involved in the mevalonate (MVA) pathway, which plays a key role in cholesterol biosynthesis: *SREBF2*, *HMGCR*, *HMGCS1*, *MVK*, *LDLR*, *INSIG1*, *ID11*, *FDFT1*. Expression of hydroxymethylglutaryl-CoA synthase (HMGCS1), a key enzyme in the MVA pathway, was assessed by Western Blot analysis and found to be reduced in PH419, PH142 and PH592-B following a single dose of eribulin (Figures 5f and 5g). In neuroblastoma, which is commonly driven by *MYCN* amplification, there is also increased activation of the MVA pathway and apparent reliance on this pathway for survival⁷¹. We hypothesise that N-MYC is a key driver of OCS, implicating the MVA pathway in OCS cell survival and drug resistance. Notably, in three of the PDX models where there was no change in HMGCS1 expression, PH003mixed,

PH003sarc and PH592-A, RNAseq showed these models had low expression of *MYCN* with maintained levels of *LIN28B* (Figure 4b), and expression of N-MYC was almost undetectable by western blot (Figures 5f and 5g). These tumours also had the poorest relative response to eribulin *in vivo* (Figure 5b).

Discussion

OCS is a rare, heterogeneous and clinically aggressive cancer, with poorer overall survival than HGSC despite a similar mutation and copy number profile^{60,61}. Nearly all patients with metastatic OCS, despite initial response to standard-of-care platinum-based chemotherapy, will succumb to their cancer due to early relapse of disease⁶². There is no effective second-line therapy available owing to its multi-drug resistant behaviour⁶². Additionally, the biphasic nature of OCS and a poor understanding of how these tumours develop has hindered progress in the development of effective treatment options.

There have been few previous molecular studies of OCS tumours where the carcinomatous and sarcomatous components have been micro- or macro-dissected^{4,5,7}. Two recent studies performed whole exome sequencing on separated components of OCS tumours, but on no more than four tumours each^{8,9}. Here, we analysed 377 genes (for mutations, copy number, or both) in 18 OCS tumours where the carcinomatous and sarcomatous components were analysed independently along with associated metastases, where available. We found mutations commonly identified in OCS, with the initial or truncal mutation likely to occur in *TP53*. In nearly all of the cases, the same *TP53* mutation was identified in all sites available; carcinoma, sarcoma and metastasis. Independent sites then developed additional mutations in most cases. Through this we definitively determined that OCS tumours in our cohort were monoclonal. Furthermore, we carried out RNAseq analysis, which has not previously been achieved for the independent components in OCS. The carcinomatous component was found to have a significantly higher EMT score than conventional HGSC, indicating these tumours may have been primed to undergo sarcomatous transformation early in carcinogenesis. Together, these data support the conversion theory for OCS histogenesis and highlight the basis of the aggressive behaviour of tumours that look, at a genomic level, indistinguishable from routine HGSC but behave like the very worst prognostic outliers. Future studies, utilising high-resolution single cell sequencing approaches, are required to prove this definitively. Nevertheless, this study, in keeping with existing published evidence^{8,9}, further emphasises the potential key role of EMT in OCS tumorigenesis and biological behaviour. This study also

highlights the potential downfall of treating women with OCS in the same way as HGSC (with the exception of *BRCA1/2*-mutant OCS cases for whom PARP inhibitor therapy is reasonable⁶³), as we have shown that despite the genomic similarity, OCS are phenotypically distinct, particularly with regard to drug responses and mesenchymal characteristics.

Similarities between OCS and the C5 molecular subtype of HGSC, as defined by Tothill *et al*³⁸, include the poor clinical outcome and link to drug resistance, as well as deregulation of the *let-7* pathway³⁶, which we have called the N-MYC/LIN28B pathway. We confirmed that *LIN28B* and *HMGA2* were significantly up-regulated in our cohort of 18 OCS tumours compared to HGSC. This suggested that the N-MYC pathway is important in the development and maintenance of OCS. Using this knowledge, we developed a GEMM of OCS by overexpressing *Lin28b* and inhibiting p53 in PAX8⁺ FTSECs. While the OCS GEMM tumours exhibited high expression of *Lin28b* and *Mycn*, the derived cell line displayed high expression of *Lin28b* and *Hmga2*, indicating that we had generated two closely related pre-clinical models of OCS with different characteristics. This demonstrates the complexity of the N-MYC pathway, as was also indicated by the RNAseq data from our patient samples. Observed expression of this pathway depends on multiple feedback loops and influences from outside the pathway, such as transcription factors, and occurs at the level of transcription and translation, frequently resulting in complex relationships⁶⁴.

These models were used to compare the current standard-of-care treatments for OCS with novel treatments, including the unique microtubule-targeting drug, eribulin, that has been shown to reverse EMT⁴²⁻⁴⁶, and has demonstrated improved efficacy against metastatic breast cancer, soft-tissue sarcoma and ovarian cancer^{48,65,66}. While the GEMM tumours were refractory to cisplatin, paclitaxel and PLD *in vivo*, they were responsive to vinorelbine and eribulin. Disease stabilisation was achieved with both vinorelbine and eribulin, suggesting a longer progression free survival may be achieved with these drugs in patients. Furthermore, after just a single dose of eribulin, a notable decrease in tumour cell proliferation was observed. To test the mechanism of action of eribulin, we used the GEMM cell line and observed significantly reduced adhesion and invasion following eribulin treatment, which corresponded with an inability of these cells to branch out in 3D matrix. Finally, an impressive reduction in expression of the mesenchymal markers ZEB1, N-cadherin, and Vimentin was observed in cells exposed to eribulin while growing on collagen, as well as in HMGA2. These results are consistent with a previous report

where eribulin reversed the process of EMT, thus reducing the mesenchymal characteristics of breast cancer cells⁴⁴.

A cohort of molecularly annotated OCS PDX models, closely resembling human OCS, were characterised for novel drug efficacy. We obtained six PDX models of OCS with a range of carcinoma and sarcoma characteristics. RNAseq analysis of these tumours indicated all OCS had higher EMT scores than HGSC, with the most carcinomatous model PH419 having the lowest EMT score and the most sarcomatous model PH003sarc having the highest EMT score. At the protein level, PH003sarc also had the highest expression of the mesenchymal markers N-cadherin and Vimentin. Interestingly, the two models containing mixed cells, PH142 and PH006 also had high expression of N-cadherin, Vimentin and ZEB1. This matched their high EMT scores obtained from the RNAseq data and indicated that pathology alone was insufficient to determine the level of sarcomatous transformation occurring in each OCS model.

Anti-microtubule agents, as a class of drug, were more effective than platinum-based chemotherapy in our diverse cohort of OCS PDX models. Interestingly, the proportion of carcinoma and sarcoma did not appear to correlate with anti-microtubule drug sensitivity. Whereas for cisplatin, the more carcinomatous PDX had some initial response, while the most sarcomatous PDX were completely refractory. Indeed, impressive responses were observed for almost all PDX to the microtubule-targeting drugs, paclitaxel, vinorelbine and eribulin. PDX PH003 was the one exception where tumours remained refractory to all treatment regimens tested. This drug-refractory PDX was later found to lack N-MYC expression, representing a particularly aggressive subtype of OCS, corresponding to rapidly progressive disease in the patient⁶⁷. Possibly as a consequence of lacking N-MYC, PH003 tumours also exhibited the lowest expression of HMGA2. Interestingly, PH592-A, the more drug-resistant lineage of PH592, also lacked expression of N-MYC, whereas it was expressed in the more drug sensitive lineage, PH592-B. Eribulin is known to reverse EMT characteristics, and indeed we observed a decrease in N-cadherin and ZEB1 protein expression in most models following a single dose of eribulin. Reduced ZEB1 and N-cadherin expression was not displayed in all of our models by IHC, which could be explained by the region of the tumour analysed. Importantly, after a single dose of eribulin, a decrease in the expression of HMGA2 was observed in PH419, PH142, PH003sarc, PH592-A and PH592-B tumours. We hypothesised that eribulin interferes with the N-MYC pathway, leading to a reduction in the mesenchymal characteristics of OCS tumours, including down-regulation of HMGA2.

To better understand the mechanism of action of eribulin in our PDX models, we carried out RNAseq analysis after a single dose of eribulin and found a significant reduction in the expression of genes involved in the MVA pathway and a significant up-regulation of genes involved in activation of immune responses. Cholesterol synthesis is important for cell membrane biogenesis and, therefore, cancer cell growth and proliferation⁶⁸. Furthermore, there are indications that cholesterol is involved in EMT^{69,70}. We hypothesised that the mechanism by which eribulin reduces EMT characteristics was by inhibiting cholesterol synthesis. To substantiate this finding, we analysed the expression of a key enzyme in the MVA pathway, HMGCS1, in PDX after a single dose of eribulin. We saw a reduction of HMGCS1 expression in four PDX. However, the three PDX that did not display reduced HMGCS1 expression after eribulin treatment lacked expression of N-MYC. We hypothesise that, as in neuroblastoma⁷¹, N-MYC drives OCS cell survival and drug resistance through the MVA pathway. This pathway appears to be targeted, at least in part, by eribulin, leading to reduced expression of N-MYC, HMGA2, and reversal of EMT characteristics.

The involvement of the MVA pathway in OCS survival suggests that statins may have therapeutic potential. However, in future studies of statins in OCS, it would be important to consider the tightly controlled SREBP2-mediated feedback loop, which acts to increase the expression of MVA pathway genes⁷². This is a potential mechanism of drug resistance, indeed it has been implicated in cisplatin resistance in ovarian cancer⁷³, which may be overcome by combination regimens⁷⁴. Considering, as we have demonstrated here, that eribulin can reduce the expression of many genes in the MVA pathway, combining eribulin with statins could potentially overcome resistance that might arise with statin therapy alone.

High levels of cholesterol have also been shown to play a protective role in cancer cells through inhibiting immune surveillance⁷⁵. Indeed, in our OCS PDX models we also observed a significant increase in the expression of genes involved in immune activation following eribulin treatment. Thus, eribulin may initiate anti-tumour immune responses in OCS, as has been observed in other tumour types^{45,47,76}. Therefore, early phase clinical trials in OCS for eribulin as a single agent and in combination with immunotherapy should be initiated to improve treatment options for OCS.

Patients and Methods:

Study conduct, survival analyses and patient samples

Overall survival was calculated from the date of diagnosis to the date of death or the last known clinical assessment. Overall survival was calculated by log-rank test (Mantel-Cox) using Prism v8.0 (GraphPad, San Diego, CA).

Formalin-fixed paraffin-embedded (FFPE) specimens were identified from the pathology archives of Queen Elizabeth University Hospital, Glasgow, UK. Following review by an expert gynaecological pathologist, areas of carcinoma and sarcoma were marked for macro-dissection.

Panel Sequencing

Libraries for sequencing were prepared from genomic DNA (gDNA) obtained from 5 x 10 μ m macro-dissected FFPE sections. A total input of 50-200ng per sample was used based on quantification with a Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad, CA, USA). Each DNA sample was sheared using a Covaris LE220 focused-ultrasonicator (Covaris, Woburn, MA, USA) with the following settings: PIP450, Cycles/Burst 200, Duty Factor 15%, Water Level of 6, shearing time of 400 seconds (executed as 350 seconds, followed by a further 50 seconds using the same settings). Pre-capture sample libraries were prepared on the SciClone G3 NGS Workstation (Perkin Elmer, Waltham, MA, USA) using SureSelect XT standard automated protocol (Agilent Technologies, Santa Clara, CA, USA) for 200ng samples. Pre-capture sample libraries were quantified with the Quant-iT PicoGreen dsDNA Assay Kit. Quantification data were used to normalise all sample libraries to 750ng in a total volume of 26.4 μ l; a full 26.4 μ l of sample library was brought forward for libraries with a total concentration too low to make this possible. Normalised pre-capture sample libraries were then captured using 120nt biotinylated custom RNA baits from a proprietary SureSelect XT custom 6-11.9Mb panel (Agilent Technologies, Santa Clara, CA, USA). Captured libraries were processed as a large panel, since more than 3Mb of sequence was intended for capture, and were incubated overnight to facilitate hybridisation, as per manufacturer's protocol. Captured sample library sequences were extracted from solution, cleaned up and prepared for post-capture PCR. Post-capture PCR incorporated primers with unique 8-bp indexes (Agilent Technologies, Santa Clara, CA, USA) for multiplexing. Amplified capture libraries were cleaned up on a Zephyr G3 NGS Workstation (Perkin Elmer, Waltham, MA, USA), using a post-PCR SPRI bead clean-up protocol (Agilent Technologies, Santa Clara, CA, USA), to

produce final capture libraries. Final captured-libraries were quantified with the Quant-iT PicoGreen dsDNA Assay Kit and assessed for size distribution and quality on a LabChip GX DNA High Sensitivity Chip (Perkin Elmer, Waltham, MA, USA). 8 uniquely indexed sample libraries were pooled per lane of a HiSeq 4000 flow cell. Pools were clustered to the flow cell using a cbot 2 system and sequenced on a HiSeq 4000 (Illumina, San Diego, CA, USA) as per manufacturer's instructions to generate 2x75bp reads.

Panel design and analysis

Genes for inclusion in the custom panel were selected from publicly available databases (including the Cancer Gene Census (CGC)⁷⁷, Database of Curated Mutations (DoCM)⁷⁸ and Vogelstein et al's analysis of COSMIC⁷⁹) as well as unbiased statistical screens⁸⁰⁻⁸³. For genes where driver events are mainly substitutions (e.g. *MAP2K1*, *GNA11*, *MTOR*, *NRAS*), the coding exons were included in the panel design. For genes where driver events are mainly copy number alterations (e.g. *CCND2*, *CCNE1*, *FGF3*, *MDM2*), approximately 20 marker SNPs spanning the gene footprint were included in the panel design. For key tumour suppressor genes (e.g. *BRCA1*, *BRCA2*, *CDKN2A*, *NF1*, *PTEN*, *RBI*) where driver events could be any inactivating sequence-level, structural or copy number change, the entire gene footprint was included in the panel design. In total, this panel assays 217 genes for coding sequence mutations, 137 genes for copy number state, and 23 genes for all genomic events. In addition, SNPs spaced approximately 1Mb apart throughout the genome were included to give a genome-wide copy number profile. Total sequence capture size was 3.465MB.

Sequencing data were analysed using HOLMES, a proprietary pipeline that uses a Snakemake⁸⁴ workflow to run the following data processing steps: 1) bcl2fastq v2.19.1 (https://support.illumina.com/sequencing/sequencing_software/bcl2fastq-conversion-software.html) or fastq generation and adapter trimming. 2) bwa mem v0.7.15⁸⁵ for alignment to GRCh38 and biobambam v2.0.72⁸⁶ for sorting, indexing, duplicate marking and duplicate removal. 3) samtools stats v1.5⁸⁷ to generate QC metrics. 4) Shearwater/deepSNV v1.22.0^{88,89} to call point mutations from properly paired reads only, using all samples from this project as the cohort, with the following filters then applied: there must be no evidence for the same mutation in the matched normal, the average mapping quality of reads supporting the variant must be ≥ 20 , the variant must not be present in the 1000 Genomes Project, at least a third of bases reporting the mutation must have a base quality of at ≥ 20 , the allele frequency of the mutation must be at

least 5%, there must be ≥ 20 reads covering the variant position and at least 3 must contain the mutation, the ratio of forward to reverse reads containing the mutation must be between 0.15 and 6.67 inclusive, not more than 10% of reads containing the mutation can contain an indel with 10 bp of the variant position. 5) Pindel v0.2.5b8⁹⁰ to call indels, with the following filters applied: only reads with a mapping quality of ≥ 10 are used as anchors, the variant must not be present in the 1000 Genomes Project, there must be no evidence for the same indel in the matched normal if it is >4 bp long or the allele frequency of the indel must be 10x higher in the tumour than in the matched normal if it is ≤ 4 bp long, at least 3 reads must report the indel, the same indel must not be called in any of the matched normals in this project, the allele frequency of the indel must be at least 5%, the ratio of forward to reverse reads containing the indel must be between 0.1 and 10 inclusive. 6) Annotation of both substitutions and indels with CAVA v1.2.2.⁹¹. 7) GeneCN v1.0 as described previously⁹² for calling the copy number state of genes and generate genome-wide copy number plots. Samples with high levels of noise, identified as those with large standard deviations within each genomic feature, were excluded from copy number analysis. This excluded WW00153c, WW00169a and WW00170c from individual analyses. 8) Brass (brass-groups command only) v5.3.3 (<https://github.com/cancerit/BRASS>) for calling structural variants (SVs) with the following filters applied: only reads with a mapping quality of ≥ 10 are considered to support an SV, ≥ 10 read pairs must support an SV, SVs must not fall within the mitochondrial genome or any unplaced or alternative contig, there must be no evidence for the same SV in the matched normal, there must be no evidence of the same SV in any of the matched normals in this project.

To compare the copy number profiles of the sarcoma and carcinoma components, GeneCN was modified to use R's scale function to centre and scale the data to account for different cellularity between samples. One profile was then subtracted from the other and calling performed on the resulting difference between the two profiles.

RNA sequencing library generation and sequencing

RNA-seq libraries for the FFPE OCS patient cohort were generated as described in TruSeq Stranded Total RNA Sample Preparation Guide (Illumina, part no. 15031048 Rev. E October 2013) using Illumina TruSeq Stranded Total RNA LT sample preparation kit. Ribosomal depletion step was performed on 500ng of total RNA using Ribo-Zero Gold (Illumina, 20020598 and 20020492). Heat fragmentation step was adjusted depending on RIN score (0 to

8 min) aimed at producing libraries with an insert size between 120-200bp. First strand cDNA was synthesised from the enriched and fragmented RNA using SuperScript II Reverse Transcriptase (Thermofisher, 18064014) and random primers. Second strand synthesis was performed in the presence of dUTP. Following 3' adenylation and ligation of adaptors to the dsDNA, libraries were subjected to 13 cycles of PCR. RNA-seq libraries were quantified using PicoGreen assay (Thermofisher, P11496) and sized and qualified using an Agilent 4200 TapeStation with Agilent D1000/High sensitivity ScreenTape (Agilent, 5067-5584). Libraries were normalised to 4nM and pooled before clustering using a cBot2 followed by 75bp paired-end sequencing on a HiSeq 4000 sequencer (Illumina).

RNAseq_V2 processed counts for HGSC from TCGA (TCGA-OV cohort) (n=396) were downloaded from the GDC portal (<https://portal.gdc.cancer.gov/>), version available on 3rd June 2019. In total, there were n = 374 files for primary tumours and n = 5 recurrent tumours. Counts were normalised across samples using DESeq2's median of ratios method⁹³. Carcinosarcoma RNAseq data (n = 27) underwent QC and was found to be satisfactory as per the parameters in FastQC (v.0.11.8 available at <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Using quasi-mapping method in Salmon version 0.8.2⁹⁴, RNAseq data was aligned to GRCh37 Ensembl release 75⁹⁵ transcriptome. Only those samples where rRNA reads account for less than 20% of the total reads were retained for the downstream analyses, n = 22 (n = 5 samples were excluded, Supplementary Figure S3). Differentially expressed genes (DEGs) between the carcinoma and sarcoma components were derived using the DESeq2 package⁹³. The Database for Annotation, Visualization and Integrated Discovery (DAVID) online Functional Annotation Tool was used for functional annotation of Differentially Expressed Genes (DEG).

For EMT gene set enrichment analysis, SingScore⁹⁶ was used with a representative directional gene set⁴⁹. Counts were normalised by rank normalisation⁹⁸ followed by the centred log-ratio transformation⁹⁷. All analyses, statistical tests, and plots were generated in R version 3.3.3 unless specified otherwise.

RNAseq libraries for the PDX tumours were prepared using TruSeq RNA Library Prep Kit v2 (Illumina), and the sequencing was performed on the Novaseq platform to read length of 100 bp (Australian Genome Research Facility). Reads were mapped to the GRCh38 Ensembl release 97 transcriptome and quantified using Kallisto⁹⁸. Counts were normalised and EMT gene set enrichment analysis undertaken as above. DEGs between treated and untreated

samples were derived using matching methods across batch and model to correct for batch effects and inherent model differences. *p*-values for DEGs were computed under a normality assumption. Topconfects⁹⁹ was used to calculate lower bounds on the effect sizes with 95% confidence.

Generation of a genetically-engineered mouse model (GEMM)

The *Pax8-rtTA* strain (C57BL/6 background) was a kind gift from Prof Ronny Drapkin (University of Pennsylvania, Department of Obstetrics and Gynecology, US). The *kai-tetOCre* strain (FVB background) was a kind gift from Prof Jane Visvader (WEHI, Melbourne, Australia) originally sourced from the Osaka Bioscience Institute, Japan. The *LSL-Lin28b* strain (mixed 129X1/SvJ background) was a kind gift from Prof Johannes H. Schulte (University Hospital Essen, Germany; Supplementary Table 14). Mice with multiple transgenes were generated through crossing and breeding mice on a mixed background, predominantly FVB/NJ and C57BL/6. Genotyping was performed using custom designed probes (TransnetYX, Inc; Supplementary Table S15). Activation of the transgenes was achieved through the administration of doxycycline, either by chow (Glen Forrest Stockfeeders SF08-026) or through drinking water (Sigma-Aldrich) at 600mg/kg or 0.2mg/ml respectively. Mice age between 3 weeks and 7 weeks and were treated for 2 weeks to allow adequate doxycycline exposure. Fallopian tubes were carefully micro-dissected, gently minced, and transplanted into the ovarian bursae of CBA/nu mice.

Immunohistochemistry

Formalin fixed tumour samples were sectioned stained with haematoxylin and eosin (H&E) as well as being sent for automatic immunostaining using the Ventana BenchMark Ultra fully automated staining instrument (Roche Diagnostics, USA). The following antibodies were used: anti-Ki67 (mouse: D3B5, Cell Signalling; human: MIB-1, Dako), anti-PAX8 (polyclonal, Proteintech), anti-p53 (mouse: CM5, Novacastra; human: DO-7, Dako), anti-PanCK (mouse: polyclonal, Abcam; human: AE1/3, Dako), anti-Vimentin (D21H3, Cell Signalling), anti-HMGA2 (D1A7, Cell Signalling), anti-N-cadherin (polyclonal, Abcam), and anti-ZEB1 (polyclonal, NovusBio). H&E and IHC slides were scanned digitally at 20x magnification using the Panoramic 1000 scanner (3DHISTECH Ltd.). High definition images were uploaded into CaseCenter (3DHISTECH Ltd.) and images were processed using FIJI image application¹⁰⁰.

600

601 **Western Blot Analysis**

602 Tumours homogenised in ice-cold RIPA buffer (50 mM Tris; pH7.5, 150 mM NaCl, 1% NP40,
603 0.5% sodium deoxycholate, 0.1% SDS in H₂O, supplemented with a complete mini protease
604 inhibitor cocktail tablet (Roche)) using Precellys Ceramic Kit tubes in the Precellys 24
605 homogenising instrument (Thermo Fisher Scientific). Proteins from lysates were separated on
606 NuPAGE® Novex® Bis-Tris 10% gels (Invitrogen). Gels were transferred onto PVDF
607 membranes using the iBlot™ Transfer system (Thermo Fish Scientific). Membranes were
608 probed with antibodies specific for ZEB1, N-cadherin, Vimentin, HMGA2 (all as mentioned
609 previously), N-MYC (D1V2A, Cell Signalling), HMGCS1 (A-6, Santa Cruz), or β-actin (AC-
610 15, Sigma).

611

612 **Sample processing for RNA and DNA**

613 Total RNA was isolated from snap-frozen cells or tumours using the Direct-zol™ RNA
614 Miniprep kit (Zymo Research) as per manufacturer's instructions. Tumour DNA was isolated
615 from snap-frozen cells or tumours using the QIAamp DNA mini kit (Qiagen) as per
616 manufacturer's instructions.

617

618 ***In vivo* studies**

619 PDX SFRC01040 was obtained from the Royal Women's Hospital under the Australian
620 Ovarian Cancer Study and generated by mixing tumour cells isolated from ascites with
621 Matrigel Matrix (Corning) and transplanting subcutaneously into NOD/SCID/IL2Rγnull
622 recipient mice (T1 = passage 1). All other PDXs were rescued through transplanting fragments
623 of cryopreserved tumour tissue subcutaneously from PDXs generated in the Mayo Clinic
624 (USA). GEMM tumours were generated as described above. Recipient mice bearing T2-T7
625 PDX or GEMM tumours (180-300 mm³ in size) were randomly assigned to cisplatin (Pfizer),
626 pegylated liposomal doxorubicin (PLD; Janssen-Cilag Pty. Ltd.), paclitaxel (Bristol-Myers
627 Squibb), vinorelbine (Pfizer), eribulin (Eisai Co., Ltd.), or vehicle treatment groups. *In vivo*
628 cisplatin treatments were performed by intraperitoneal (IP) injection of 4 mg/kg given on days
629 1, 8 and 18. The regimen for PLD treatment was by IP injection once a week for three weeks
630 at 1.5 mg/kg. The regimen for paclitaxel treatment was by IP injection twice a week for three
631 weeks at 25 mg/kg. The regimen for vinorelbine was by intravenous injection of 15 mg/kg at
632 days 1, 8 and 18. The regimen for eribulin treatment was by IP injection three times a week for

three weeks at 1.5 mg/kg (with the exception of mice harbouring SFRC01040 tumours, which received doses of 1 mg/kg with the same scheduling). Vehicle for cisplatin, PLD, paclitaxel, vinorelbine and eribulin treatment was Dulbecco's Phosphate Buffered Saline (DPBS). Electronic calliper measurements of the primary tumour size were taken twice a week until tumours reached 600-700 mm³ or when mice reached ethical endpoint. Data collection was conducted using the Studylog LIMS software (Studylog Systems, San Francisco). Graphing and statistical analysis was conducted using the SurvivalVolume package¹⁰¹.

Cisplatin *in vivo* response in PDX was assessed as previously described⁵⁹. One hundred days was chosen as a conservative measure to differentiate between cisplatin sensitivity versus resistance for PDX. We defined response as being "cisplatin sensitive" if the average PDX tumour volume of the recipient mice underwent initial tumour regression with complete remission (CR, defined as tumour volume < 50 mm³) or partial remission (PR, defined as reduction in tumour volume of >30% from baseline) followed by progressive disease (PD, an increase in tumour volume of >20% from 200 mm³ or nadir post-treatment, if nadir ≥ 200 mm³) occurring ≥ 100 days from start of treatment; "cisplatin resistant" if initial tumour regression (CR or PR) or stable disease (SD) was followed by PD within 100 days; or "cisplatin refractory" if three or more mice bearing that PDX had tumours which failed to respond (no CR, PR or SD) during cisplatin treatment (day 1-18).

Time to progression (TTP or PD), time to harvest (TTH), and treatment responses are as defined previously⁵⁹. Stable disease (SD) was achieved if TTP for the treatment group was at least twice as long as TTP for corresponding vehicle treated group.

Generation of cell lines

An OCS GEMM cell line was generated from a T1 OCS GEMM tumour. Briefly, the tumour was manually minced into a slurry using two scalpel blades and resuspended in DMEM/F-12 GlutaMAX medium (Gibco) supplemented with 10% fetal calf serum (FCS). Cell fragments were subsequently plated on 0.1% gelatin coated plate and passaged aggressively within 3-4 days to retain viable malignant adherent cells until a stable cell line was obtained at p12 onward. Cell identity was confirmed by genotyping (as for GEMM tumours). OCS GEMM cells were grown in DMEM/F-12 GlutaMAX medium (Gibco) supplemented with 10% FCS, 50 ng/mL EGF and 1 µg/mL hydrocortisone in 5% CO₂ at 37°C.

666

667 **Adhesion, invasion assays and 3D growth assays**

668 Adhesion assays were carried out in 96-well plates pre-coated with 2% BSA or 20 µg/ml
 669 collagen. GEMM cells were pre-treated for a week with DMSO (vehicle control), 0.2 µM
 670 cisplatin or 20 nM eribulin. Pre-treated cells were plated at a cell density of 2×10^5 cells/well
 671 in triplicate in pre-coated wells and allowed to adhere for 2 hours. Non-adherent cells were
 672 aspirated and adherent cells stained with 100 µl of 0.5% crystal violet (Sigma) dissolved in
 673 20% methanol for 15 min at room temperature. Stained cells were solubilised with 50 µl of 0.1
 674 M citrate buffer in 50% methanol. Adherent cells were quantified by measuring absorbance at
 675 595 nm on a Chameleon Luminescence Plate Reader (Noki Technologies). Transwell
 676 migration and invasion assays were carried out as previously described¹⁰². Briefly, 2.5×10^5
 677 pre-treated GEMM cells (as above) were seeded into Matrigel-coated transwells and medium
 678 supplemented with 10% FCS placed in the bottom wells to act as a chemoattractant. Parallel
 679 assays were carried out in uncoated control transwell inserts to assess cell migration in the
 680 absence of extracellular matrix (ECM). 3D growth assays were carried out as previously
 681 described¹⁰². Briefly, wells of a 48-well plate were pre-coated with 1.5 mg/mL collagen
 682 (Thermo Fisher Scientific) in DMEM and incubated at room temperature until collagen became
 683 solid. Pre-treated (as above) or untreated GEMM OCS cells were resuspended in 1.5 mg/mL
 684 collagen/DMEM, plated at 0.02×10^5 cells/well, and incubated at room temperature until
 685 collagen became solid. Medium was added to each well and cells incubated at 37°C/5% CO₂
 686 for 8-10 days.

687

688 **Statistical Analysis**

689 Data was analysed using the Student t-test unless otherwise stated and considered significant
 690 when the *p* value was <0.05. All statistical tests were two-sided. Bar graphs represent the mean
 691 and standard error across independent experimental repeats unless otherwise stated. Survival
 692 analysis was performed using the log rank test on Kaplan-Meier survival function estimates.
 693 Statistical significance representations: **p*<0.05, ***p*<0.01, ****p*<0.001.

694

695 **Ethics**

696 Samples for the UK cohort were acquired and utilised under the authority of the NHS Greater
 697 Glasgow and Clyde Biorepository (Application Reference 286) following approval by West of
 698 Scotland Research Ethics Committee 4 (Reference 10/S0704/60). All animal studies and

procedures were approved by the Walter and Eliza Hall Institute of Medical Research (WEHI) Animal Ethics Committee (#2019.024) and performed following guidelines for the welfare and use of animals in cancer research.

Acknowledgements

We thank S. Stoev, R. Hancock, and K. Barber for technical assistance. We thank Prof Ronny Drapkin, Prof Jane Visvader (and Osaka Bioscience Institute, Japan), and Prof Johannes H. Schulte for kind gifts of the mouse strains used to generate the GEMM. We thank Eisai Co., Ltd. for supply of eribulin. This work was supported by fellowships and grants from the National Health and Medical Research Council (NHMRC Australia; Project grants 1062702 (CLS) and 1104348 (CLS and MJW), Senior Research Fellowship 1116955 (ATP)); the Stafford Fox Medical Research Foundation (CLS, HEB, JB, ATP); the Lorenzo and Pamela Galli Charitable Trust (ATP); Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research to CLS and Ovarian Cancer Research Grant-in-Aid 1186314 to CIA HEB, CIC CJV and CID GR); the Victorian Cancer Agency (Clinical Fellowships to CLS CRF10-20, CRF16014); CRC for Cancer Therapeutics (PhD top-up scholarship to GH); Research Training Program Scholarship (PhD Scholarship to GH). This work was made possible through the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. The Scottish Genomes Partnership is funded by the Chief Scientist Office of the Scottish Government Health Directorates (grant reference SGP/1) and The Medical Research Council Whole Genome Sequencing for Health and Wealth Initiative. Additional funding was provided by the Medical Research Council (the Glasgow Molecular Pathology Node, grant reference MR/N005813/1), Cancer Research UK (grant references A15973 [IMcN] and A17263 [AVB]), the Wellcome Trust (grant reference 103721/Z/14/Z [AVB]) and the Beatson Cancer Charity (grant reference 15-16-051 [IMcN, PR]). Support was also provided by Ovarian Cancer Action, the Cancer Research UK Centres and Experimental Cancer Medicine Centres at both Glasgow and Imperial and the NIHR Imperial Biomedical Research Centre.

The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania and The Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182) and the National Health and Medical Research Council of Australia (NHMRC; ID199600; ID400413 and ID400281).

The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. The AOCS also acknowledges the cooperation of the participating institutions in Australia and acknowledges the contribution of the study nurses, research assistants and all clinical and scientific collaborators to the study. The complete AOCS Study Group can be found at www.aocstudy.org. We would like to thank all of the women who participated in these research programs.

Author contributions

C.L.S., M.J.W., I.A.M., H.E.B, and A.T.P. designed the study, developed methodology, analysed data, wrote the manuscript and supervised the study. G.Y.H. and E.L.K. performed experiments, analysed data, and wrote the manuscript. J.B. analysed data, supervised the study and reviewed the manuscript. E.L., C.J.V. and O.K., developed methodology, performed experiments, analysed data and reviewed the manuscript. D.P.E., R.U.-G., U.-M.B., S.D., G.B. and G.R. performed experiments and reviewed the manuscript. H.B.M. analysed data, wrote and reviewed the manuscript. P.R., R.M.G. and A.V.B. supervised the study and reviewed the manuscript. S.L.C designed the study, developed methodology, analysed data, supervised the study and reviewed the manuscript. O.McN., A. DeF., J.W. and D.D.B. acquired data or samples, supervised the study and reviewed the manuscript. N.T. acquired data, provided administrative support and reviewed the manuscript. AOCS acquired data and reviewed the manuscript.

Conflicts of interest

Disclosure of Potential Conflicts of interest: Eisai Inc provided drug support for this study. RMG declares Advisory boards for Clovis, Tesaro and AstraZeneca. AVB declares Personal and Financial interest in BMS, AstraZeneca, MyTomorrows, Elstar Therapeutics, IP Financial Interest in Agilent Technologies, Leadership role, stock ownership in Cumulus Oncology, Nodus Oncology, ConcR, Cambridge Cancer Genomics. IAMcN declares Advisory Boards for Clovis Oncology, Tesaro/GSK, AstraZeneca, Roche, Scancell, Carrick Therapeutics, Takeda Oncology; Institutional grant support from AstraZeneca. DDB declares Consultant for Exo Therapeutics. Research Support for AstraZeneca, Roche, GNE, Beigene. CLS declares Advisory Boards for AstraZeneca, Clovis Oncology, Roche, Eisai Inc, Sierra Oncology, Takeda, MSD and Grant/Research support from Clovis Oncology, Eisai Inc, Sierra Oncology, Roche and Beigene. Other authors declare no conflicts of interest.

References

1. Rauh-Hain, J.A., *et al.* Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. *Gynecol Oncol* **142**, 38-43 (2016).
2. Mano, M.S., *et al.* Current management of ovarian carcinosarcoma. *Int J Gynecol Cancer* **17**, 316-324 (2007).
3. Rauh-Hain, J.A., Birrer, M. & Del Carmen, M.G. "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities". *Gynecol Oncol* **142**, 248-254 (2016).
4. Abeln, E.C., *et al.* Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. *J Pathol* **183**, 424-431 (1997).
5. Growdon, W.B., *et al.* Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. *Gynecol Oncol* **121**, 212-217 (2011).
6. Jin, Z., *et al.* Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. *Int J Gynecol Pathol* **22**, 368-373 (2003).
7. Kounelis, S., *et al.* Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. *Hum Pathol* **29**, 82-87 (1998).
8. Gotoh, O., *et al.* Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. *Nat Commun* **10**, 4965 (2019).
9. Zhao, S., *et al.* Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. *Proc Natl Acad Sci U S A* **113**, 12238-12243 (2016).
10. del Carmen, M.G., Birrer, M. & Schorge, J.O. Carcinosarcoma of the ovary: a review of the literature. *Gynecol Oncol* **125**, 271-277 (2012).
11. Costa, M.J., Vogelsan, J. & Young, L.J. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): a clinicopathologic study of 74 cases. *Mod Pathol* **7**, 619-627 (1994).
12. Fujii, H., *et al.* Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. *Cancer Res* **60**, 114-120 (2000).
13. Liu, F.S., *et al.* Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. *Obstet Gynecol* **83**, 118-124 (1994).
14. Cantrell, L.A. & Van Le, L. Carcinosarcoma of the ovary a review. *Obstet Gynecol Surv* **64**, 673-680; quiz 697 (2009).
15. Jones, S., *et al.* Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. *Nat Commun* **5**, 5006 (2014).
16. Carnevali, I.W., *et al.* Two Cases of Carcinosarcomas of the Ovary Involved in Hereditary Cancer Syndromes. *Int J Gynecol Pathol* **36**, 64-70 (2017).
17. Pennington, K.P., *et al.* Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. *Clin Cancer Res* **20**, 764-775 (2014).
18. Herzog, T., Xiu, J., Bender, R., Gatalica, Z. & Reddy, S. BRCA1 and BRCA2 mutations in 1691 epithelial ovarian tumors identify subgroups with distinct molecular characteristics. *European Journal of Cancer* **51**, S554-S555 (2015).

- 815 19. Sonoda, Y., Saigo, P.E., Federici, M.G. & Boyd, J. Carcinosarcoma of the ovary in a
816 patient with a germline BRCA2 mutation: evidence for monoclonal origin. *Gynecol*
817 *Oncol* **76**, 226-229 (2000).
- 818 20. Morishita, A., *et al.* HMGA2 is a driver of tumor metastasis. *Cancer Res* **73**, 4289-4299
819 (2013).
- 820 21. Elton, T.S., Nissen, M.S. & Reeves, R. Specific A . T DNA sequence binding of RP-
821 HPLC purified HMG-I. *Biochem Biophys Res Commun* **143**, 260-265 (1987).
- 822 22. Reeves, R. & Nissen, M.S. The A.T-DNA-binding domain of mammalian high mobility
823 group I chromosomal proteins. A novel peptide motif for recognizing DNA structure.
824 *J Biol Chem* **265**, 8573-8582 (1990).
- 825 23. Solomon, M.J., Strauss, F. & Varshavsky, A. A mammalian high mobility group protein
826 recognizes any stretch of six A.T base pairs in duplex DNA. *Proc Natl Acad Sci U S A*
827 **83**, 1276-1280 (1986).
- 828 24. Strauss, F. & Varshavsky, A. A protein binds to a satellite DNA repeat at three specific
829 sites that would be brought into mutual proximity by DNA folding in the nucleosome.
830 *Cell* **37**, 889-901 (1984).
- 831 25. Gattas, G.J., Quade, B.J., Nowak, R.A. & Morton, C.C. HMGIC expression in human
832 adult and fetal tissues and in uterine leiomyomata. *Genes Chromosomes Cancer* **25**,
833 316-322 (1999).
- 834 26. Rogalla, P., *et al.* HMGI-C expression patterns in human tissues. Implications for the
835 genesis of frequent mesenchymal tumors. *Am J Pathol* **149**, 775-779 (1996).
- 836 27. Chang, K.P., *et al.* Low-molecular-mass secretome profiling identifies HMGA2 and
837 MIF as prognostic biomarkers for oral cavity squamous cell carcinoma. *Sci Rep* **5**,
838 11689 (2015).
- 839 28. Piscuoglio, S., *et al.* HMGA1 and HMGA2 protein expression correlates with advanced
840 tumour grade and lymph node metastasis in pancreatic adenocarcinoma.
841 *Histopathology* **60**, 397-404 (2012).
- 842 29. Saada-Bouazid, E., *et al.* Prognostic value of HMGA2, CDK4, and JUN amplification
843 in well-differentiated and dedifferentiated liposarcomas. *Mod Pathol* **28**, 1404-1414
844 (2015).
- 845 30. Sun, M., *et al.* RKIP and HMGA2 regulate breast tumor survival and metastasis through
846 lysyl oxidase and syndecan-2. *Oncogene* **33**, 3528-3537 (2014).
- 847 31. Wang, X., *et al.* Overexpression of HMGA2 promotes metastasis and impacts survival
848 of colorectal cancers. *Clin Cancer Res* **17**, 2570-2580 (2011).
- 849 32. Lee, Y.S. & Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2
850 oncogene. *Genes Dev* **21**, 1025-1030 (2007).
- 851 33. Mayr, C., Hemann, M.T. & Bartel, D.P. Disrupting the pairing between let-7 and
852 Hmga2 enhances oncogenic transformation. *Science* **315**, 1576-1579 (2007).
- 853 34. Park, S.M., *et al.* Let-7 prevents early cancer progression by suppressing expression of
854 the embryonic gene HMGA2. *Cell Cycle* **6**, 2585-2590 (2007).
- 855 35. Shell, S., *et al.* Let-7 expression defines two differentiation stages of cancer. *Proc Natl*
856 *Acad Sci U S A* **104**, 11400-11405 (2007).
- 857 36. Helland, A., *et al.* Deregulation of MYCN, LIN28B and LET7 in a molecular subtype
858 of aggressive high-grade serous ovarian cancers. *PLoS One* **6**, e18064 (2011).
- 859 37. Wang, T., *et al.* Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human
860 malignant tumors and its effects on the hallmarks of cancer. *Mol Cancer* **14**, 125 (2015).
- 861 38. Tothill, R.W., *et al.* Novel molecular subtypes of serous and endometrioid ovarian
862 cancer linked to clinical outcome. *Clin Cancer Res* **14**, 5198-5208 (2008).
- 863 39. Mahajan, A., *et al.* HMGA2: a biomarker significantly overexpressed in high-grade
864 ovarian serous carcinoma. *Mod Pathol* **23**, 673-681 (2010).

- 865 40. Jordan, M.A., *et al.* The primary antimitotic mechanism of action of the synthetic
866 halichondrin E7389 is suppression of microtubule growth. *Mol Cancer Ther* **4**, 1086-
867 1095 (2005).
- 868 41. Okouneva, T., Azarenko, O., Wilson, L., Littlefield, B.A. & Jordan, M.A. Inhibition of
869 centromere dynamics by eribulin (E7389) during mitotic metaphase. *Mol Cancer Ther*
870 **7**, 2003-2011 (2008).
- 871 42. Funahashi, Y., *et al.* Eribulin mesylate reduces tumor microenvironment abnormality
872 by vascular remodeling in preclinical human breast cancer models. *Cancer Sci* **105**,
873 1334-1342 (2014).
- 874 43. Kawano, S., Asano, M., Adachi, Y. & Matsui, J. Antimitotic and Non-mitotic Effects
875 of Eribulin Mesilate in Soft Tissue Sarcoma. *Anticancer Res* **36**, 1553-1561 (2016).
- 876 44. Yoshida, T., *et al.* Eribulin mesilate suppresses experimental metastasis of breast cancer
877 cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to
878 mesenchymal-epithelial transition (MET) states. *Br J Cancer* **110**, 1497-1505 (2014).
- 879 45. Ito, K., *et al.* Antitumor effects of eribulin depend on modulation of the tumor
880 microenvironment by vascular remodeling in mouse models. *Cancer Sci* **108**, 2273-
881 2280 (2017).
- 882 46. Ueda, S., *et al.* In vivo imaging of eribulin-induced reoxygenation in advanced breast
883 cancer patients: a comparison to bevacizumab. *Br J Cancer* **114**, 1212-1218 (2016).
- 884 47. Kashiwagi, S., *et al.* Use of Tumor-infiltrating lymphocytes (TILs) to predict the
885 treatment response to eribulin chemotherapy in breast cancer. *PLoS One* **12**, e0170634
886 (2017).
- 887 48. Schoffski, P., *et al.* Eribulin versus dacarbazine in previously treated patients with
888 advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre,
889 phase 3 trial. *Lancet* **387**, 1629-1637 (2016).
- 890 49. Chiyoda, T., *et al.* Expression profiles of carcinosarcoma of the uterine corpus-are these
891 similar to carcinoma or sarcoma? *Genes Chromosomes Cancer* **51**, 229-239 (2012).
- 892 50. Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma.
893 *Nature* **474**, 609-615 (2011).
- 894 51. Byers, L.A., *et al.* An epithelial-mesenchymal transition gene signature predicts
895 resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for
896 overcoming EGFR inhibitor resistance. *Clin Cancer Res* **19**, 279-290 (2013).
- 897 52. Mak, M.P., *et al.* A Patient-Derived, Pan-Cancer EMT Signature Identifies Global
898 Molecular Alterations and Immune Target Enrichment Following Epithelial-to-
899 Mesenchymal Transition. *Clin Cancer Res* **22**, 609-620 (2016).
- 900 53. Tan, T.Z., *et al.* Epithelial-mesenchymal transition spectrum quantification and its
901 efficacy in deciphering survival and drug responses of cancer patients. *EMBO Mol Med*
902 **6**, 1279-1293 (2014).
- 903 54. Laviolette, L.A., *et al.* 17beta-estradiol accelerates tumor onset and decreases survival
904 in a transgenic mouse model of ovarian cancer. *Endocrinology* **151**, 929-938 (2010).
- 905 55. Molenaar, J.J., *et al.* LIN28B induces neuroblastoma and enhances MYCN levels via
906 let-7 suppression. *Nat Genet* **44**, 1199-1206 (2012).
- 907 56. Schonig, K., Schwenk, F., Rajewsky, K. & Bujard, H. Stringent doxycycline dependent
908 control of CRE recombinase in vivo. *Nucleic Acids Res* **30**, e134 (2002).
- 909 57. Traykova-Brauch, M., *et al.* An efficient and versatile system for acute and chronic
910 modulation of renal tubular function in transgenic mice. *Nat Med* **14**, 979-984 (2008).
- 911 58. Sherman-Baust, C.A., *et al.* A genetically engineered ovarian cancer mouse model
912 based on fallopian tube transformation mimics human high-grade serous carcinoma
913 development. *J Pathol* **233**, 228-237 (2014).

- 914 59. Topp, M.D., *et al.* Molecular correlates of platinum response in human high-grade
915 serous ovarian cancer patient-derived xenografts. *Mol Oncol* **8**, 656-668 (2014).
- 916 60. Rauh-Hain, J.A., *et al.* Carcinosarcoma of the ovary: a case-control study. *Gynecol*
917 *Oncol* **121**, 477-481 (2011).
- 918 61. Brackmann, M., *et al.* Comparison of first-line chemotherapy regimens for ovarian
919 carcinosarcoma: a single institution case series and review of the literature. *BMC*
920 *Cancer* **18**, 172 (2018).
- 921 62. Ebata, T., *et al.* Treatment Outcome of Second-Line Chemotherapy for Gynecologic
922 Carcinosarcoma. *Oncology*, 1-7 (2020).
- 923 63. Norquist, B.M., *et al.* Inherited Mutations in Women With Ovarian Carcinoma. *JAMA*
924 *Oncol* **2**, 482-490 (2016).
- 925 64. Balzeau, J., Menezes, M.R., Cao, S. & Hagan, J.P. The LIN28/let-7 Pathway in Cancer.
926 *Front Genet* **8**, 31 (2017).
- 927 65. Cortes, J., *et al.* Eribulin monotherapy versus treatment of physician's choice in patients
928 with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
929 *Lancet* **377**, 914-923 (2011).
- 930 66. Hensley, M.L., *et al.* Eribulin mesylate (halichondrin B analog E7389) in platinum-
931 resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. *Cancer* **118**,
932 2403-2410 (2012).
- 933 67. Glaser, G., *et al.* Conventional chemotherapy and oncogenic pathway targeting in
934 ovarian carcinosarcoma using a patient-derived tumorgraft. *PLoS One* **10**, e0126867
935 (2015).
- 936 68. Mullen, P.J., Yu, R., Longo, J., Archer, M.C. & Penn, L.Z. The interplay between cell
937 signalling and the mevalonate pathway in cancer. *Nat Rev Cancer* **16**, 718-731 (2016).
- 938 69. Morandi, A., Taddei, M.L., Chiarugi, P. & Giannoni, E. Targeting the Metabolic
939 Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive
940 Tumors. *Front Oncol* **7**, 40 (2017).
- 941 70. Sciacovelli, M. & Frezza, C. Metabolic reprogramming and epithelial-to-mesenchymal
942 transition in cancer. *Febs j* **284**, 3132-3144 (2017).
- 943 71. Liu, M., *et al.* Transcriptional Profiling Reveals a Common Metabolic Program in
944 High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.
945 *Cell Rep* **17**, 609-623 (2016).
- 946 72. Longo, J., *et al.* An actionable sterol-regulated feedback loop modulates statin
947 sensitivity in prostate cancer. *Mol Metab* **25**, 119-130 (2019).
- 948 73. Zheng, L., Li, L., Lu, Y., Jiang, F. & Yang, X.A. SREBP2 contributes to cisplatin
949 resistance in ovarian cancer cells. *Exp Biol Med (Maywood)* **243**, 655-662 (2018).
- 950 74. Pandyra, A.A., *et al.* Genome-wide RNAi analysis reveals that simultaneous inhibition
951 of specific mevalonate pathway genes potentiates tumor cell death. *Oncotarget* **6**,
952 26909-26921 (2015).
- 953 75. Novak, A., *et al.* Cholesterol masks membrane glycosphingolipid tumor-associated
954 antigens to reduce their immunodetection in human cancer biopsies. *Glycobiology* **23**,
955 1230-1239 (2013).
- 956 76. Goto, W., *et al.* Eribulin Promotes Antitumor Immune Responses in Patients with
957 Locally Advanced or Metastatic Breast Cancer. *Anticancer Res* **38**, 2929-2938 (2018).
- 958 77. Futreal, P.A., *et al.* A census of human cancer genes. *Nat Rev Cancer* **4**, 177-183
959 (2004).
- 960 78. Ainscough, B.J., *et al.* DoCM: a database of curated mutations in cancer. *Nat Methods*
961 **13**, 806-807 (2016).
- 962 79. Vogelstein, B., *et al.* Cancer genome landscapes. *Science* **339**, 1546-1558 (2013).

963 80. Kandoth, C., *et al.* Mutational landscape and significance across 12 major cancer types.
964 *Nature* **502**, 333-339 (2013).

965 81. Lawrence, M. & Morgan, M. Scalable Genomics with R and Bioconductor. *Stat Sci* **29**,
966 214-226 (2014).

967 82. Tamborero, D., Gonzalez-Perez, A. & Lopez-Bigas, N. OncodriveCLUST: exploiting
968 the positional clustering of somatic mutations to identify cancer genes. *Bioinformatics*
969 **29**, 2238-2244 (2013).

970 83. Zack, T.I., *et al.* Pan-cancer patterns of somatic copy number alteration. *Nat Genet* **45**,
971 1134-1140 (2013).

972 84. Koster, J. & Rahmann, S. Snakemake--a scalable bioinformatics workflow engine.
973 *Bioinformatics* **28**, 2520-2522 (2012).

974 85. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-
975 MEM. (2013).

976 86. Tischler, G. & Leonard, S. biobambam: tools for read pair collation based algorithms
977 on BAM files. *Source Code for Biology and Medicine* **9**, 13 (2014).

978 87. Li, H., *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**,
979 2078-2079 (2009).

980 88. Gerstung, M., Papaemmanuil, E. & Campbell, P.J. Subclonal variant calling with
981 multiple samples and prior knowledge. *Bioinformatics* **30**, 1198-1204 (2014).

982 89. Gerstung, M., *et al.* Reliable detection of subclonal single-nucleotide variants in tumour
983 cell populations. *Nat Commun* **3**, 811 (2012).

984 90. Ye, K., Schulz, M.H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth
985 approach to detect break points of large deletions and medium sized insertions from
986 paired-end short reads. *Bioinformatics* **25**, 2865-2871 (2009).

987 91. Munz, M., *et al.* CSN and CAVA: variant annotation tools for rapid, robust next-
988 generation sequencing analysis in the clinical setting. *Genome Med* **7**, 76 (2015).

989 92. Cooke, S.L., *et al.* The driver mutational landscape of ovarian squamous cell
990 carcinomas arising in mature cystic teratoma. *Clin Cancer Res* **34**, 7633-7640 (2017).

991 93. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and
992 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).

993 94. Patro, R., Duggal, G., Love, M.I., Irizarry, R.A. & Kingsford, C. Salmon provides fast
994 and bias-aware quantification of transcript expression. *Nat Methods* **14**, 417-419
995 (2017).

996 95. Flicek, P., *et al.* Ensembl 2014. *Nucleic Acids Res* **42**, D749-755 (2014).

997 96. Foroutan, M., *et al.* Single sample scoring of molecular phenotypes. *BMC*
998 *Bioinformatics* **19**, 404 (2018).

999 97. Aitchison, J. The Statistical Analysis of Compositional Data. *Journal of the Royal*
1000 *Statistical Society: Series B (Methodological)* **44**, 139-160 (1982).

1001 98. Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-
1002 seq quantification. *Nat Biotechnol* **34**, 525-527 (2016).

1003 99. Harrison, P.F., Pattison, A.D., Powell, D.R. & Beilharz, T.H. Topconfects: a package
1004 for confident effect sizes in differential expression analysis provides a more
1005 biologically useful ranked gene list. *Genome Biol* **20**, 67 (2019).

1006 100. Schindelin, J., *et al.* Fiji: an open-source platform for biological-image analysis. *Nat*
1007 *Methods* **9**, 676-682 (2012).

1008 101. Wakefield, M.J. Survival volume: interactive volume threshold survival graphs. *The*
1009 *Journal of Open Source Software* **1**(8), 111 (2016).

1010 102. Barker, H.E., *et al.* LOXL2-mediated matrix remodeling in metastasis and mammary
1011 gland involution. *Cancer Res* **71**, 1561-1572 (2011).

1012

Main Tables and Figures

Table 1: *In vivo* responses of GEMM tumours to cisplatin, paclitaxel, pegylated liposomal doxorubicin (PLD), vinorelbine and eribulin

Treatment	Number of mice (n)	Time to progressive disease (PD) (days)	Median time to harvest (TTH) (days)	p value Compared to vehicle	p value Compared to cisplatin	p value Compared to eribulin	p value Compared to paclitaxel	p value Compared to doxorubicin liposomal	p value Compared to vinorelbine	Drug response score
Vehicle	25	7	15							
Cisplatin	10	7	18	0.0251		0.2063	0.9378		<0.0001	Refractory
Paclitaxel	3	7	36	0.0101	0.9378	0.0067		0.4855	0.0006	Refractory
PLD	3	7	29	0.0798	0.5834	0.0043	0.4855		0.0002	Refractory
Vinorelbine	9	56	81	<0.0001	<0.0001	0.0012	0.0006	0.0002		Responsive
Eribulin	5	35	46	<0.0001	0.2063		0.0067	0.0043	0.0012	Responsive

The GEMM tumours were refractory to cisplatin, paclitaxel and PLD as the time to progressive disease (PD) was the same as for vehicle treated mice. PLD and cisplatin failed to demonstrate any meaningful response with no significant difference in median time-to-harvest (TTH) compared to vehicle treatment. Paclitaxel demonstrated modest responses with an increase in median TTH from 15 to 36 days compared to vehicle treated mice ($p = 0.0101$). Improvement in time to PD were seen in tumours treated with vinorelbine (56 days) and eribulin (35 days). This led to a significant improvement of median TTH from 15 days for vehicle treated mice to 81 days with vinorelbine ($p < 0.0001$) and to 46 days with eribulin ($p < 0.0001$). The log-rank test was used for statistical analysis of Kaplan-Meier survival curves (Figure 3a).

Table 2: *In vivo* responses of OCS PDXs to cisplatin, paclitaxel, vinorelbine and eribulin

PDX model	Treatment	Number of mice (n)	Time to progressive disease (PD) (days)	Median time to harvest (TTH) (days)	p value Compared to vehicle	p value Compared to cisplatin	p value Compared to eribulin	p value Compared to paclitaxel	p value Compared to vinorelbine	Drug response score (Topp et al)
SFRC01040	Vehicle	8	7	53						
	Cisplatin	8	60	120	0.0008					Resistant
	Eribulin	7	>120	>120	0.0015	0.0511		>0.9999	>0.9999	Sensitive
	Paclitaxel	7	>120	>120	0.0013	0.0511	>0.9999		>0.9999	Sensitive
	Vinorelbine	6	>120	>120	0.0033	0.1232	>0.9999	>0.9999		Sensitive
PH419	Vehicle	23	7	15						
	Cisplatin	13	7	39	<0.0001					Refractory
	Eribulin	8	>120	>120	<0.0001	0.0016		0.0875	0.0446	Sensitive
	Paclitaxel	14	112	120	<0.0001	0.0036	0.0875		0.6489	Sensitive
	Vinorelbine	12	80	99	<0.0001	0.0151	0.0446	0.6489		Resistant
PH142	Vehicle	31	7	15						
	Cisplatin	19	42	71	<0.0001					Resistant
	Eribulin	10	77	99	<0.0001	0.0042		0.8113	0.4092	Resistant
	Paclitaxel	22	57	95	<0.0001	<0.0001	0.8113		0.1134	Resistant
	Vinorelbine	19	120	106	<0.0001	<0.0001	0.4092	0.1134		Sensitive
PH006	Vehicle	17	7	22						
	Cisplatin	9	7	39	0.0064					Refractory
	Eribulin	6	>120	>120	0.0005	0.0079		0.4795	>0.9999	Sensitive
	Paclitaxel	7	>120	>120	<0.0001	0.0024	0.4795		0.3173	Sensitive
	Vinorelbine	7	>120	>120	<0.0001	0.0012	>0.9999	0.3173		Sensitive
PH003	Vehicle	23	7	8						
	Cisplatin	19	7	15	0.0005					Refractory
	Eribulin	14	7	25	0.0003	0.0044		0.9612	0.1339	Refractory
	Paclitaxel	16	7	29	<0.0001	0.0025	0.9612		0.0666	Refractory
	Vinorelbine	13	18	32	<0.0001	0.0005	0.1339	0.0666		Refractory
PH592	Vehicle	18	7	15						
	Cisplatin	7	7	15	0.0335					Refractory
	Eribulin	8	80	92	<0.0001	<0.0001		0.2838	0.3070	Resistant
	Paclitaxel	8	88	102	<0.0001	<0.0001	0.2838		0.2183	Resistant
	Vinorelbine	9	63	71	<0.0001	<0.0001	0.3070	0.2183		Resistant

1041

1042 Cisplatin failed to achieve any meaningful tumour response in four of six PDX models; PH419,

1043 PH006, PH003 and PH592, with a time to development of progressive disease (PD) during

1044 cisplatin treatment. PH142 and SFRC01040 demonstrated some response to cisplatin with

improvement of median TTH from 15 to 71 days ($p < 0.0001$) and 53 to 120 days ($p = 0.0008$), compared to vehicle treated mice, respectively. However, times to PD were less than 100 days (PH142 at 42 days and SRFC01040 at 60 days), therefore these tumours were classified as resistant to cisplatin. Three of six PDX (SFRC01040, PH419 and PH006) were shown to be sensitive to paclitaxel *in vivo*, two PDX (PH142 and PH592) were resistant and one PDX (PH003) was refractory based on the same *in vivo* drug response score as cisplatin. Paclitaxel treated PDX models displayed an impressive improvement in median TTH compared with vehicle treated mice except for PH003 (53 to >120 days for SFRC01040 ($p = 0.0013$), 15 to 120 days for PH419 ($p < 0.0001$), 15 to 95 days for PH142 ($p < 0.0001$), 22 to >120 days for PH006 ($p < 0.0001$), and 15 to 102 days for PH592 ($p < 0.0001$)). Significant improvements in median TTH compared to cisplatin treated mice were observed for four models (39 to 120 days for PH419 ($p = 0.0036$), 71 to 95 days for PH142 ($p < 0.0001$), 39 to >120 days for PH006 ($p = 0.0024$), and 15 to 102 days for PH592 ($p < 0.0001$)). Three of six OCS PDX (SFRC01040, PH142 and PH006) were sensitive, two PDXs (PH419 and PH592) were resistant and one PDX (PH003) was refractory to vinorelbine treatment. Significant improvements of median TTH compared with vehicle treated mice were observed for all models treated with vinorelbine except for PH003 (53 to >120 days for SFRC01040 ($p = 0.0033$), 15 to 99 days for PH419 ($p < 0.0001$), 15 to 106 days for PH142 ($p < 0.0001$), 22 to >120 days for PH006 ($p < 0.0001$), and 15 to 71 days for PH592 ($p < 0.0001$)). There were significant improvements in median TTH compared with cisplatin treated mice were also observed for four models (120 to >120 days for SFRC01040 ($p = 0.1232$), 39 to 99 days for PH419 ($p = 0.0151$), 71 to 106 days for PH142 ($p < 0.0001$), 39 to >120 days for PH006 ($p = 0.0012$), and 15 to 71 days for PH592 ($p < 0.0001$)). Three of six OCS PDX models (SFRC01040, PH419 and PH006) were sensitive, two PDX (PH412 and PH592) were resistant and one PDX (PH003) was refractory to eribulin treatment. Significant improvements of median TTH were observed in eribulin treated mice compared to vehicle for five models (53 to >120 days for SFRC01040 ($p = 0.0015$), 15 to 99 days for PH142 ($p < 0.0001$), 22 to >120 days for PH006 ($p = 0.0005$), 15 to >120 days for PH419 ($p < 0.0001$), and 15 to 92 days for PH592 ($p = <0.0001$)). Lastly, significant improvements in median TTH compared with cisplatin treated mice were also observed for four models (120 to >120 days for SFRC01040 ($p = 0.0511$), 39 to >120 days for PH419 ($p = 0.0016$), 71 to 99 days for PH142 ($p = 0.0042$), 39 to >120 days for PH006 ($p = 0.0079$), 15 to 25 days for PH003 ($p = 0.0044$), and 15 to 92 days for PH592 ($p < 0.0001$)). The log-rank test was used for statistical analysis of Kaplan-Meier survival curves (Figure 5a).

1091

Figure 2

1092

1093 **Figure 2: Generation and characterisation of a GEMM of OCS.** (A) A *Pax8-rtTA; kai-*
1094 *tetO-Cre; LSL-Lin28b/SV40TAG* transgenic mouse was treated with doxycycline for 2 weeks
1095 to induce expression of Cre recombinase in the FTSECs. The FTs were then removed, minced
1096 and transplanted into the ovarian bursa of a *cba/Nu* host mouse, generating the GEMM founder
1097 tumour (T0). This tumour was transplanted into mice to establish the first and subsequent OCS
1098 cohorts (T1, T2, T3, etc). A T1 tumour was also digested and cultured *in vitro* to generate a

1099 cell line. **(B)** The GEMM T0 founder tumour and a tumour generated after the 1st transplant
1100 (T1) were assessed by IHC. T0 and T1 tumours expressed PAX8, indicating FTSEC derivation.
1101 Representative images of H&E, PAX8, p53, Pan-CK and Vimentin staining are shown. Scale
1102 bars represent 100µm. **(C)** The GEMM T0 founder tumour, T1 tumours (n=4) and the GEMM
1103 cell line grown in 2D and 3D were analysed by RNA-seq. Controls included normal FT tissue
1104 harvested from FVB mice, and FT epithelial cells and stroma. A heatmap shows the expression
1105 of genes involved in the N-MYC/LIN28B pathway: *Lin28b*, *Mycn* and *Hmga2*. GEMM,
1106 genetically engineered mouse model; FTSEC, fallopian tube secretory epithelial cell; FTE,
1107 fallopian tube epithelium; OSE, ovarian surface epithelium; CK, cytokeratin; FT, fallopian
1108 tube; CLR, centred log ratio.

Figure 3

Figure 3: GEMM OCS tumours are refractory to current standard-of-care treatments for ovarian cancer but are responsive to the microtubule drugs vinorelbine and eribulin. (A) *In vivo* treatment of GEMM OCS tumours with: DPBS (n=25), cisplatin (4mg/kg; n=10), PLD (1.5mg/kg; n=3), paclitaxel (n=3), vinorelbine (15mg/kg; n = 9) and eribulin (1.5mg/kg; n=5). Shaded area = 95% confidence interval. Time to PD and harvest (TTH) are shown in

1115 Table 1. **(B)** Expression of Ki67 was assessed by IHC in a number of tumours after a single
1116 dose of eribulin (or DPBS vehicle). Representative images are shown. Scale bars represent
1117 100µm. **(C)** GEMM cells were pre-treated with eribulin (20 nM), cisplatin (0.2 µM) or vehicle
1118 control (DMSO) for one week before being plated in adhesion assays (left panel) or migration
1119 and invasion assays (right panel). Percentage of adherent cells was calculated compared to
1120 vehicle-treated controls. Percentage of invading cells was calculated compared to number of
1121 migrating cells. **(D)** GEMM cells were pre-treated as above with eribulin, cisplatin or vehicle
1122 control (DMSO) for one week before being plated in collagen with treatment either removed
1123 or maintained. Representative images of colonies growing in collagen on day 8 are shown.
1124 Scale bars represent 200µm. **(E)** Expression of the mesenchymal markers ZEB1, N-cadherin,
1125 Vimentin and HMGA2 in cells exposed to 50nM eribulin or DMSO control for the indicated
1126 time-points was determined by Western Blot analysis. β-actin was used as a loading control.
1127 PLD, pegylated liposomal doxorubicin; PD, progressive disease; IHC, immunohistochemistry.
1128
1129
1130

Figure 4

1131

1132

Figure 4: Characterisation of PDX models of OCS with varying proportions of carcinoma and sarcoma (A) Tumours from each PDX model of OCS were assessed by IHC. Representative images of H&E, Ki67, p53, PAX8, Pan-CK, Vimentin and HMGA2 staining are shown. Scale bars represent 100µm. SFRC01040 and PH419 were almost purely carcinoma, PH142, PH006 and PH003 were mixed with both carcinomatous and sarcomatous characteristics (i.e. expressing both Pan-CK and Vimentin) and PH592 was purely sarcomatous, with some epithelial characteristics (i.e. Pan-CK co-expression in some cells). (B) Expression of *HMGA2*, *LIN28B* and *MYCN* were determined from RNAseq data for each OCS model (n = 3) compared to ovarian high-grade serous carcinoma samples in TCGA (n = 379). (C) EMT scores generated from RNAseq data for tumours from each OCS PDX model are shown compared with EMT scores for ovarian high-grade serous carcinoma samples in TCGA. (D) Expression of the mesenchymal markers ZEB1, N-cadherin, Vimentin and HMGA2 in tumours from each OCS PDX model was determined by Western Blot analysis. β -actin was used as a loading control. PDX, patient-derived xenograft; IHC, immunohistochemistry; CK, cytokeratin; TCGA-OV, ovarian high-grade serous carcinomas in TCGA; EMT, epithelial-to-mesenchymal transition; CLR, centred log ratio.

Figure 5

1149

1150

Figure 5: PDX OCS tumours are refractory to cisplatin but display mostly impressive responses to microtubule drugs. (A) *In vivo* treatment of OCS PDX tumours with DPBS, cisplatin (4mg/kg), paclitaxel (25mg/kg), vinorelbine (15mg/kg) and eribulin (1.5mg/kg, with the exception of mice harbouring SFRC01040 tumours, which received doses of 1mg/kg). n values for each model are shown in Table 2. Shaded area = 95% confidence interval. More carcinomatous models are shown on the top left and the more sarcomatous models on the bottom right. Time to PD and harvest (TTH) are shown in Table 2. (B) Expression of the mesenchymal markers ZEB1 and N-cadherin in tumours from each OCS PDX model after a single dose of vehicle (DPBS) or eribulin was determined by Western Blot analysis. β -actin was used as a loading control. (C) Quantification of expression data in (B). (D) Expression of HMGA2 in tumours from each OCS PDX model after a single dose of vehicle (DPBS) or eribulin was determined by IHC. Scale bars represent 100 μ m. (E) Analysis of GO terms enriched for down-regulated (red) and up-regulated (green) DEGs. Circle sizes indicate DEGs present in each GO term. DEGs are listed in Supplementary Tables S18 - S21. (F) Expression of N-MYC and HMGCS1 in tumours from each OCS PDX model after a single dose of vehicle (DPBS) or eribulin was determined by Western Blot analysis. β -actin was used as a loading control. (G) Quantification of expression data in (F). GO, gene ontology; DEG, differentially expressed gene; FDR, false discovery rate.